NCT04983901: PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN |
|
|
| Completed | 2 | 100 | US | Imipenem/Cilastatin/Relebactam, RECARBRIO™, Cefepime, Meropenem, Meropenem Trihydrate, Merrem I.V., SM-7338, Piperacillin-Tazobactam, PIPER/TAZO, Piperacillin/Tazobactam, Zosyn, Vancomycin, Daptomycin, Cubicin, LY146032, Linezolid, Zyvox | M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC | Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | 10/23 | 10/23 | | |
